Table 4.
Study, Yr | Subjects on TNFi | Mean age (yr) |
Subjects on Comparator DMARD |
Follow up period | Findings |
---|---|---|---|---|---|
Lange, 2005(23) | 26 IFX | 54 | - | 1 year | BMD increased by 12% at the femoral neck and 3% at the lumbar spine |
Vis, 2005(27) | 36 IFX | 53 | - | 1 year | BMD remained stable at the spine and hip |
Vis, 2006(26) | 102 IFX | 53 | - | 1 year | BMD remained stable at the spine and hip |
Seriolo, 2006(25) | 11 ETA and 10 IFX | 51 | 10 MTX | 6 months | BMD increased by 0.1–0.2% at the spine and hip among TNFi users and decreased by 0.6–0.8% at the spine and hip among MTX users |
Marotte, 2007(44) | 90 IFX | 51 | 99 MTX | 1 year | BMD decreased by 2.5–3.9% at the spine and femoral neck in the control group, but remained stable in the IFX group |
Serelis, 2008(24) | 7 ADA and 12 IFX | 54 | - | 1 year | BMD remained stable at the spine |
Chopin, 2008(18) | 48 IFX | 54 | - | 54 weeks | BMD remained stable at the spine |
Haugeberg, 2009(20) | 10 IFX | 52 | 10 MTX | 1 year | BMD loss was significantly less in the infliximab group compared with the placebo group at the femoral neck (−0.4% vs. −3.4%) and total hip (−0.2% vs. −2.6%) but not at the hand and spine |
Wijbrandts, 2009(28) | 52 ADA | 51 | - | 1 year | BMD remained stable at the spine and femur neck |
Hoff, 2009(22) | 522 ADA | 52 | 246 MTX | 104 weeks | Hand BMD loss was lowest in the ADA plus MTX group and greatest in the MTX group (−3.0% vs. −4.6%) |
Güler-Yüksel, 2009(19) | 52 IFX | 54 | 166 on other treatment | 2 years | Hand BMD loss was less in the IFX group compared with other treatment only |
Eekman, 2011(21) | 52 IFX | 60 | - | 3.5 years | BMD was stable at the hip, increased by 2.6% at the spine, and decreased by 3.1% in the hand |
Hoff, 2011(43) | 214 ADA | 52 | 188 MTX | 2 years | Hand bone loss was less in the ADA plus MTX group, independently of clinically assessed disease activity |
TNFi: tumor necrosis factor-α inhibitor, BMD: bone mineral density, IFX: infliximab, ADA, adalimumab, ETA: etanercept, MTX: methotrexate, DMARD: disease-modifying antirheumatic drug